Prostamax

Overview

Prostamax is a Khavinson bioregulator tetrapeptide (KEDP) with primary repair effects on prostate tissue. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it alters chromatin structure in cells from elderly individuals, promoting deheterochromatinization and potentially reactivating genes repressed during aging. Research in rat models shows reduced prostate inflammation, decreased swelling, and decelerated pathological remodeling associated with prostatitis.

Mechanism of action

Prostamax works through epigenetic regulation by altering chromatin structure. It increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin. These changes promote chromatin decondensation and deheterochromatinization, potentially reactivating genes repressed during aging. The peptide influences heterochromatin arrangements in human lymphocytes and normalizes age-related changes in cellular function.

Key research findings

• Reduces prostate inflammation
• Decreases prostatic swelling
• Reduces vascular congestion (hyperemia)
• Decreases immune cell infiltration
• Reduces scarring in prostate tissue
• Promotes chromatin decondensation
• Reactivates age-repressed genes
• Improves lymphocyte function

Research applications

Prostate Health

• Chronic Prostatitis — Research shows reduced inflammation and swelling in prostatitis models.
• Prostatic Inflammation — Mitigates inflammation and immune cell infiltration in prostate tissue.
• Prostate Tissue Repair — Decreases scarring and pathological remodeling in prostate.

Anti-Aging

• Chromatin Remodeling — Promotes deheterochromatinization in elderly cells.
• Gene Reactivation — Potentially reactivates genes repressed during aging process.
• Lymphocyte Function — Normalizes age-related changes in lymphocyte function.